CLONICEL (Clonidine Sustained Release) as Add-on to Stimulant Medication in 6 to 17 Yr-olds With ADHD
NCT ID: NCT00641329
Last Updated: 2010-04-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
198 participants
INTERVENTIONAL
2008-02-29
2009-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Evaluating the Safety and Efficacy of CLONICEL® to Treat Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
NCT00556959
Open-Label, Chronic Exposure, Safety Study of CLONICEL (Clonidine HCl Sustained Release) in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
NCT00723190
Clonidine in Attention Deficit Hyperactivity Disorder (ADHD) in Children
NCT00031395
A Study to Assess the Effectiveness and Safety of Clonidine Extended-Release OnydaTM XR in Children With ADHD and ODD
NCT07044609
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
NCT01081132
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
CLONICEL (clonidine HCl sustained release)
Flexible Dose (0.1 - 0.4 mg)
2
Placebo
Matching placebo tablets
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CLONICEL (clonidine HCl sustained release)
Flexible Dose (0.1 - 0.4 mg)
Placebo
Matching placebo tablets
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of ADHD
* Currently on a stable psychostimulant regimen for ADHD
* Lack of adequate response to stable psychostimulant regimen
* Ability to swallow tablets
Exclusion Criteria
* Conduct Disorder
* Intolerance to clonidine
* History of seizures or syncope
6 Years
17 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Addrenex Pharmaceuticals, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Addrenex Pharmaceuticals
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Moise Khayrallah, PhD
Role: STUDY_DIRECTOR
Addrenex Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Little Rock, Arkansas, United States
El Centro, California, United States
Irvine, California, United States
San Diego, California, United States
Bradenton, Florida, United States
Lauderhill, Florida, United States
Miami, Florida, United States
Bardstown, Kentucky, United States
Baltimore, Maryland, United States
St Louis, Missouri, United States
Clementon, New Jersey, United States
Chapel Hill, North Carolina, United States
Durham, North Carolina, United States
Cleveland, Ohio, United States
Oklahoma City, Oklahoma, United States
Oklahoma City, Oklahoma, United States
Houston, Texas, United States
Houston, Texas, United States
Lake Jackson, Texas, United States
Wharton, Texas, United States
Clinton, Utah, United States
Kirkland, Washington, United States
Spokane, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLON-302
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.